Posted On: 11/28/2015 4:16:01 PM
Post# of 193
Hedge Funds Bullish on VRX (Valeant Pharmaceuticals)
Scott Mclellan increased its stake in Valeant Pharmaceuticals Intl (NYSE:VRX) by 11.96% based on its latest Q3 2015 regulatory filing with the SEC. Marble Arch Investments Lp bought 127,900 shares as the company’s stock declined 21.85% with the market. The hedge fund run by Scott Mclellan held 1.20 million shares of the health care company at the end of Q3, valued at $213.50M, up from 1.07 million at the end of the previous reported quarter. Marble Arch Investments Lp who had been investing in Valeant Pharmaceuticals Intl since many months, is probably bullish the $30.28 billion market cap company. The stock decreased 0.18% or $0.16 on November 27, hitting $86.86. About 4.22M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 56.89% since April 27, 2015.
Marble Arch Investments Lp, which manages about $1.96 billion and $1.30 billion US Long portfolio, decreased its stake in Aspen Technology Inc (NASDAQ:AZPN) by 634,061 shares to 2.47 million shares, valued at $93.56 million in Q3, according to the filing.
Marble Arch Investments was established in 2007 by Scott McLellan, who had beforehand worked at Hound Partners. Dog’s supervisor, Jonathan Auerbach, is a Tiger Cub thus McLellan can follow his speculation ancestry to Julian Robertson too. McLellan himself worked at Highbridge Capital Management and has a MBA from Northwestern. Marble Arch is a long/short value reserve. Marble Arch Investments Lp is a New York-based hedge fund that was founded by Scott Mclellan. It had more than $1.96 billion assets under management in February, 2014. Taken from Marble Arch Investments latest Adv, the fund reported to have 15 full and part-time employees. Among which 9 performing investment advisory and research functions. The hedge fund had between 1-10 clients.
Scott Mclellan increased its stake in Valeant Pharmaceuticals Intl (NYSE:VRX) by 11.96% based on its latest Q3 2015 regulatory filing with the SEC. Marble Arch Investments Lp bought 127,900 shares as the company’s stock declined 21.85% with the market. The hedge fund run by Scott Mclellan held 1.20 million shares of the health care company at the end of Q3, valued at $213.50M, up from 1.07 million at the end of the previous reported quarter. Marble Arch Investments Lp who had been investing in Valeant Pharmaceuticals Intl since many months, is probably bullish the $30.28 billion market cap company. The stock decreased 0.18% or $0.16 on November 27, hitting $86.86. About 4.22M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 56.89% since April 27, 2015.
Marble Arch Investments Lp, which manages about $1.96 billion and $1.30 billion US Long portfolio, decreased its stake in Aspen Technology Inc (NASDAQ:AZPN) by 634,061 shares to 2.47 million shares, valued at $93.56 million in Q3, according to the filing.
Marble Arch Investments was established in 2007 by Scott McLellan, who had beforehand worked at Hound Partners. Dog’s supervisor, Jonathan Auerbach, is a Tiger Cub thus McLellan can follow his speculation ancestry to Julian Robertson too. McLellan himself worked at Highbridge Capital Management and has a MBA from Northwestern. Marble Arch is a long/short value reserve. Marble Arch Investments Lp is a New York-based hedge fund that was founded by Scott Mclellan. It had more than $1.96 billion assets under management in February, 2014. Taken from Marble Arch Investments latest Adv, the fund reported to have 15 full and part-time employees. Among which 9 performing investment advisory and research functions. The hedge fund had between 1-10 clients.
(0)
(0)
